Opus Genetics(formerly Ocuphire Pharma)

Farmington Hills, United States

Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

Apr 2026

Post-IPO Debt

Biopharma Biotechnology Pharmaceutical

Top Investors

Balyasny Asset ManagementAdage Capital ManagementPerceptive AdvisorsOberland CapitalMarshall Wace

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Opus Genetics(formerly Ocuphire Pharma)

Who are Opus Genetics(formerly Ocuphire Pharma)'s investors?

Opus Genetics(formerly Ocuphire Pharma)'s investors include Balyasny Asset Management, Adage Capital Management, Perceptive Advisors, Oberland Capital, Marshall Wace.

Where is Opus Genetics(formerly Ocuphire Pharma) headquartered?

Opus Genetics(formerly Ocuphire Pharma) is headquartered in Farmington Hills, United States.

What does Opus Genetics(formerly Ocuphire Pharma) do?

Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

What stage is Opus Genetics(formerly Ocuphire Pharma) at?

Opus Genetics(formerly Ocuphire Pharma) is at the Post-IPO Debt stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 6, 2026.

MLA

"Opus Genetics(formerly Ocuphire Pharma) — Funding & Investors." VCBacked, April 6, 2026, https://www.vcbacked.co/company/opus-geneticsformerly-ocuphire-pharma. Accessed June 24, 2026.

APA

VCBacked. (2026). Opus Genetics(formerly Ocuphire Pharma) — Funding & Investors. Retrieved June 24, 2026, from https://www.vcbacked.co/company/opus-geneticsformerly-ocuphire-pharma

Wikipedia (cite web)

{{cite web |title=Opus Genetics(formerly Ocuphire Pharma) — Funding & Investors |url=https://www.vcbacked.co/company/opus-geneticsformerly-ocuphire-pharma |website=VCBacked |access-date=June 24, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 6, 2026.